BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 6, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 25, 2020
View Archived Issues
Capsid-like particles displaying an HA trimer: a promising universal flu vaccine candidate
Read More
New partner in crime for AHR
Read More
Multiple sclerosis' early days
Read More
New ADCs including tandem-cleavage linkers show improved stability and toxicity
Read More
Epigenetic problems contribute to Parkinson's disease
Read More
Roche reports the discovery of novel CYP11B2 inhibitors
Read More
Tocilizumab may prevent risk of invasive mechanical ventilation or death in severe COVID-19
Read More
Bayer, The Broad Institute describe new PDE3A and/or PDE3B inhibitors
Read More
FDA clears IND application for phase Ib study of NT-I7 plus Kymriah in r/r LBCL
Read More
Positive topline data presented from phase III CONTESSA study of tesetaxel
Read More
Orexin receptor type 1 antagonists discovered at Heptares Therapeutics
Read More
Hubei Bio-Pharmaceutical, Humanwell Healthcare patent E-NPP 2 inhibitors
Read More
Bristol-Myers Squibb discovers TYK2 inhibitors
Read More
New adenosine A2A/A2B receptor antagonists identified at Incyte
Read More
Pivotal phase III INSPIRE study of rigosertib in MDS does not meet primary endpoint
Read More
Keytruda receives two new approvals in Japan
Read More
Imugene begins phase I study of IMU-201 in NSCLC
Read More
Early clinical reports suggest utility of Aggrastat for COVID-19-related thrombotic complications
Read More
AstraZeneca begins first-in-human study of AZD-7442 for prevention and treatment of COVID-19
Read More